Immunotherapy choice and maintenance for generalized myasthenia gravis in China.

ABSTRACT:

Aims

To compare long-term efficacy and safety of immunotherapeutic strategies as maintenance to prevent disease relapses of generalized myasthenia gravis (MG) in real-world settings.

Methods

This is a retrospective cohort study on generalized MG conducted in seven major neurological centers across China. Eligible participants were patients with generalized MG who were under minimal manifestation status or better. Main outcome measures were probability of patients free of relapses and causes of drug discontinuation.

Results

Among 1064 patients enrolled, the median (interquartile range) age was 50.3 (37.0-62.5) years and 641 (60.2%) were women. Disease relapse was significantly lower for rituximab (6.1%) compared with all the other monotherapies (hazard ratio [HR] = 0.1

SUBMITTER: Zhang C 

PROVIDER: S-EPMC7702233 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature